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Summary
Background Smoking has been linked to mucinous ovarian cancer, but its eﬀ ects on other ovarian cancer subtypes 
and on overall ovarian cancer risk are unclear, and the ﬁ ndings from most studies with relevant data are unpublished. 
To assess these associations, we review the published and unpublished evidence.
Methods Eligible epidemiological studies were identiﬁ ed by electronic searches, review articles, and discussions with 
colleagues. Individual participant data for 28 114 women with and 94 942 without ovarian cancer from 51 epidemiological 
studies were analysed centrally, yielding adjusted relative risks (RRs) of ovarian cancer in smokers compared with 
never smokers.
Findings After exclusion of studies with hospital controls, in which smoking could have aﬀ ected recruitment, overall 
ovarian cancer incidence was only slightly increased in current smokers compared with women who had never 
smoked (RR 1·06, 95% CI 1·01–1·11, p=0·01). Of 17 641 epithelial cancers with speciﬁ ed histology, 2314 (13%) were 
mucinous, 2360 (13%) endometrioid, 969 (5%) clear-cell, and 9086 (52%) serous. Smoking-related risks varied 
substantially across these subtypes (pheterogeneity<0·0001). For mucinous cancers, incidence was increased in current 
versus never smokers (1·79, 95% CI 1·60–2·00, p<0·0001), but the increase was mainly in borderline malignant 
rather than in fully malignant tumours (2·25, 95% CI 1·91–2·65 vs 1·49, 1·28–1·73; pheterogeneity=0·01; almost half the 
mucinous tumours were only borderline malignant). Both endometrioid (0·81, 95% CI 0·72–0·92, p=0·001) and 
clear-cell ovarian cancer risks (0·80, 95% CI 0·65–0·97, p=0·03) were reduced in current smokers, and there was no 
signiﬁ cant association for serous ovarian cancers (0·99, 95% CI 0·93–1·06, p=0·8). These associations did not vary 
signiﬁ cantly by 13 sociodemographic and personal characteristics of women including their body-mass index, parity, 
and use of alcohol, oral contraceptives, and menopausal hormone therapy.
Interpretation The excess of mucinous ovarian cancers in smokers, which is mainly of tumours of borderline 
malignancy, is roughly counterbalanced by the deﬁ cit of endometrioid and clear-cell ovarian cancers. The substantial 
variation in smoking-related risks by tumour subtype is important for understanding ovarian carcinogenesis.
Funding Cancer Research UK and MRC.
Introduction
Until recently, smoking was not thought to be a risk 
factor for ovarian cancer, but in 2009 the International 
Agency for Research on Cancer added mucinous ovarian 
tumours (which comprise about a tenth of all ovarian 
cancers) to their list of tobacco-related cancers.1 We 
identiﬁ ed 56 epi demiological studies of ovarian cancer 
that obtained information about women’s smoking 
history. Some results have been published from 55 of the 
56 studies,2–56 but results on smoking-related risks have 
been pub lished from only about a third of these stud-
ies.4,5,10,15,16,18,20,23,27,32,34,35,43,44,46,50,53,54,56 Almost all reported little or 
no association between smoking and overall risk of 
ovarian cancer; some, but not all, reported an increased 
risk of mucinous tumours in smokers, but not for other 
subtypes of ovarian cancer.
The Collaborative Group on Epidemiological Studies of 
Ovarian Cancer was set up to bring together and 
reanalyse the available epidemiological evidence, pub-
lished and unpublished, on the association between 
various factors and ovarian cancer risk.57 To avoid 
selective emphasis on results from the few studies that 
have published their ﬁ ndings, this report sought data 
from all studies larger than a speciﬁ c size that have 
obtained relevant information about the relation between 
ovarian cancer risk and women’s smoking history, 
whether published or not.
Methods
Search strategy and selection criteria
This collaboration began in 1998, and since then 
potentially eligible epidemiological studies have been 
sought regularly by searches of review articles and from 
computer-aided literature searches in Medline, Embase, 
and PubMed, with combinations of the search terms 
“ovarian cancer”, “ovary cancer”, “smok*”, and “tobacco”. 
To be eligible for these analyses, studies needed to have 
obtained individual data for women’s reproductive 
history, use of hormonal therapies, and smoking history 
and to have studied at least 200 women with ovarian 
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cancer (before 2006, studies with less than 200 cases of 
ovarian cancer had been eligible, so there are fewer cases 
in some early studies). Studies that had obtained relevant 
data, but had not published on ovarian cancer and 
smoking, were sought by correspondence with col-
leagues, by discussions at collaborators meetings, and by 
electronic searches with additional terms “cohort”, 
“prospective”, “women”, and “cancer risk”.
We identiﬁ ed 56 eligible studies and invited principal 
investigators from each to participate in the collabor-
ation. Investigators from two eligible studies52,53 did not 
respond to our enquiries and those from three other 
eligible studies54–56 were unable to participate. Thus, 
data from 51 of the 56 eligible studies identiﬁ ed are 
analysed in this report, and implications of the slight 
incompleteness are discussed later.
Data extraction
Cases were women with malignant epithelial (borderline 
malignant or fully malignant) or with non-epithelial 
ovarian cancer and controls were women without ovarian 
cancer who had not undergone bilateral oophorectomy. 
Information sought from principal investigators about 
each individual case and control included their age, 
ethnic group, education, alcohol and tobacco use, height, 
weight or body-mass index (BMI), age at menarche, 
reproductive history, use of hormonal contraceptives, use 
of menopausal hormonal therapy, hysterectomy, 
and family history of ovarian or breast cancer. The 
information sought about these factors related to the 
time preceding the onset of symptoms for cases and to 
an equivalent time for controls. So that similar analytical 
methods could be used across studies, we incorporated 
cohort studies using a nested case–control design, in 
which up to four controls were selected at random, 
matched by age at cancer diagnosis and, where 
appropriate, by broad geographical region. In one cohort 
study,21 cases were women with fatal ovarian cancer, 
whereas in all other studies cases were women with 
incident disease.
Principal investigators of the 51 epidemiological stud-
ies (one of which is unpublished) in these analyses2–51 
provided individual information about smoking history 
for cases and controls. The analyses used information 
provided by principal investigators about a woman’s 
smoking history before the onset of symptoms. For 
retrospective case–control studies, this was smoking 
history before the onset of symptoms for cases and at an 
equivalent time for controls. For prospective studies, 
principal investigators generally provided information 
about women’s smoking history recorded at the time 
they were recruited into the cohort. The information 
provided was used to classify all women as ever or never 
smokers, and in all but three studies7,14,45 ever smokers 
could be classiﬁ ed as either current or past smokers. 
Information about amount smoked and timing of 
exposure was sought only for the few studies that joined 
the collaboration after 2009, so reliable analyses of 
these aspects of smoking could not be done. All data 
contributed by principal investigators were checked and 
collated centrally so that analyses could use deﬁ nitions 
that were as similar as possible across studies. Apparent 
inconsistencies in the data were rectiﬁ ed, where possible, 
Number of 
cases/controls
Median year of 
diagnosis of 
cases
Median year of 
birth of cases
Mean age at 
diagnosis of 
cases (years)
19 prospective studies
Oxford/FPA (UK)12 49/196 1988 1937 48·1
BCDDP (USA)37 220/1184 1991 1925 65·3
Nurses’ Health Study (USA)46 663/2707 1991 1930 58·7
RCGP (UK)14 176/704 1991 1936 52·8
IOWA Women’s Health (USA)28 175/705 1991 1924 68·1
Radiation technologists (USA)36 45/177 1992 1945 47·6
Netherlands Cohort26 261/1805 1992 1923 67·9
CNBSS (Canada)27 483/1932 1993 1932 59·2
Norwegian Counties30 130/520 1993 1937 55·1
CPS-II Mortality (USA)21 2554/10 718 1994 1923 70·3
CPS-II Nutrition (USA)38 349/1399 1997 1929 67·7
Southern Swedish25 73/293 1997 1938 57·4
WLH (Norway/Sweden)43 106/427 1998 1947 48·8
NIH-AARP (USA)47 763/3052 1999 1932 65·9
EPIC (Europe)50 769/3099 2000 1939 59·8
NOWAC (Norway)29 78/326 2000 1937 61·4
PLCO (USA)49 202/807 2001 1933 68·2
Swedish mammography48 89/498 2001 1936 65·7
Million Women Study (UK)41 3608/14 341 2002 1941 61·0
All prospective studies 10 793/44 890 1999 1934 63·5
21 case–control studies with population controls
Weiss (USA)6 298/1137 1977 1921 55·1
Cramer I (USA)3 248/238 1979 1926 51·5
CASH (USA)16 575/4233 1981 1937 41·9
Whittemore (USA)4 234/683 1984 1933 50·5
Shu/Brinton (China)7 228/229 1985 1933 48·4
Western New York (USA)24 117/686 1988 1930 58·3
Risch (Canada)11 450/564 1991 1934 56·7
Green/Purdie (Australia)18 793/854 1992 1935 55·2
Mosgaard (Denmark)13 907/1071 1992 1943 45·9
Cramer II (USA)15 563/525 1993 1942 51·1
Riman (Sweden)32 802/3361 1994 1932 61·6
German OCS22 281/533 1995 1937 55·1
Pike/Wu (USA)31 477/660 1995 1939 55·5
Goodman/Wu (USA)23 720/895 1996 1942 55·0
NISOC study (Israel)19 1342/2262 1996 1938 56·6
OVCARE (USA)40 378/1637 1996 1950 45·7
SHARE (USA)20 767/1367 1996 1943 51·6
Newcomb (Two States; USA)39 498/3163 1998 1942 55·0
Polish Study42 299/1994 2002 1947 55·4
AOCS (Australia)44 1426/1492 2004 1946 56·6
HOPE (USA)51 670/1551 2005 1948 57·1
All with population controls 12 073/29 135 1995 1940 53·8
(Continues on next page)
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by correspondence with the investigators. After the 
records had been checked and corrected, investigators 
were sent summary tables and listings of the variables to 
be used in analyses for ﬁ nal conﬁ rmation that their data 
had been correctly interpreted.
Information about histological classiﬁ cation and 
malignant potential of the ovarian cancers was sought 
from principal investigators. Tumours were classiﬁ ed as 
epithelial, non-epithelial, or malignant not otherwise 
speciﬁ ed (NOS). The epithelial cancers were then 
classiﬁ ed as clear-cell, endometrioid, mucinous, serous, 
other, mixed, or NOS, and were further subdivided by 
their malignant potential as borderline malignant, fully 
malignant, and not known whether borderline or fully 
malignant. If investigators provided International 
Classiﬁ cation of Diseases for Oncology58 codes, these were 
used to classify tumours centrally. Information about 
ovarian cancer histology was provided by investigators of 
all but ﬁ ve9,10,12,21,36 of the 51 participating studies; not all 
studies had included non-epithelial and borderline 
malignant ovarian cancer.
Statistical analysis
We used conditional logistic regression to calculate the 
relative risk (RR) of ovarian cancer in relation to smoking 
history (ie, the incidence rate ratio among otherwise 
similar women of the same age, calculated as the ratio of 
the odds of smoking among cases to the odds of smoking 
among controls). To ensure that women in one study 
were compared directly only with otherwise similar 
women in the same study, all analyses were routinely 
stratiﬁ ed by study, by centre within study, by ﬁ ne 
divisions of age (5-year age groups up to 85–89 years), 
ever use of menopausal hormonal therapy (yes, no), 
menopausal status or hysterectomy (premenopausal 
or perimenopausal, natural menopause before age 
50 years, natural menopause at or after age 50 years, 
previous hysterectomy, other or unknown), and BMI 
(<25 kg/m², ≥25 kg/m²) and were routinely adjusted by 
parity (0, 1–2, ≥3) and use of oral contraceptives (no or 
yes for durations of <5 years and ≥5 years). For other 
potential confounding factors (year of birth, ethnic 
origin, education, family history of ovarian or breast 
cancer, age at menarche, and alcohol use), we did 
sensitivity analyses comparing results before and after 
adjustment for each variable in turn and for all 
simultaneously. Unknowns for each stratiﬁ cation and 
adjustment variable were assigned to separate groups. 
We made comparisons across diﬀ erent subgroups of 
women using standard χ² tests for heterogeneity, 
calculated from the change in log likelihood on adding 
extra terms. Signiﬁ cance tests for heterogeneity of the 
eﬀ ect of smoking by tumour subtype were based on 
analyses within cases only, because controls provide no 
additional information. Smoking status was treated as a 
dichotomous outcome (current vs never) and the term for 
tumour subtype was treated as the variable of interest in 
a conditional logistic regression, stratiﬁ ed and adjusted 
as described previously.
Analyses were done using STATA (version 11). Results 
in the ﬁ gures are presented with squares and lines. The 
position of the square shows the value of the RR and its 
area is inversely proportional to the variance of the 
logarithm of the RR, thereby providing an indication of 
the amount of statistical information available for that 
particular estimate. When results from many studies, 
many tumour subtypes, or many subgroups are 
presented in the ﬁ gures, the lines show 99% CIs (rather 
than 95% CIs) to help to allow for multiple testing. When 
the main results are given in the text, however, 95% CIs 
are used.
Role of the funding source
The funders had no role in study design, data collection, 
analysis or interpretation of data, preparation of the 
report, or the decision to publish. All members of the 
analysis and writing committee (VB, KG, CH, KM, RP, 
GR) had access to the raw data and are responsible for 
the ﬁ nal submission for publication.
Results
Table 1 shows details of the women in the 51 participating 
studies. The studies are grouped by their design and, 
within each type of design, are ordered by the median 
year when the ovarian cancers were diagnosed. All but 
eight of the studies were done in North America or 
Europe, and all but six in high-income countries. 
Over all, the studies contributed 28 114 women 
with ovarian cancer (cases) and 94 942 women without 
ovarian cancer (controls), with 10 362 (37%) cases from 
Europe and 12 817 (46%) from North America. 1423 (5%) 
Number of 
cases/controls
Median year of 
diagnosis of 
cases
Median year of 
birth of cases
Mean age at 
diagnosis of 
cases (years)
(Continued from previous page)
11 case–control studies with hospital controls
Newhouse (UK)2 293/597 1973 1918 54·2
Booth (UK)5 288/491 1980 1927 50·9
Tzonou/Tricopoulos (Greece)10 150/249 1980 1924 55·5
Rosenberg (USA)34 950/3808 1983 1935 49·5
Negri/Franceschi (Italy)9 972/2481 1986 1932 53·1
WHO (developing)8 177/6474 1986 1943 40·0
PEDS (USA)35 418/1765 1989 1933 54·7
Negri (Italy)17 1031/2408 1995 1939 54·9
Zhejiang-Curtin (China)33 287/652 1999 1952 46·3
Johannesburg (South Africa)45 182/1492 2001 1945 54·7
Guangzhou (China), unpublished 500/500 2006 1947 58·6
All with hospital controls 5248/20 917 1990 1937 52·7
All 51 studies 28 114/94 942 1995 (1991–2000) 1937 (1928–45) 57·3 (12·4)
Data in parentheses are IQR or SD.
Table 1: Studies and women included
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women were younger than 35 years at diagnosis, 
2696 (10%) were aged 35–44 years, 6467 (23%) were 
45–54 years, 9206 (33%) were 55–64 years, and 
8322 (30%) were 65 years or older. Similar percentages 
of cases and controls reported having ever smoked.
Figure 1 shows study-speciﬁ c results for ever versus 
never smokers, with studies grouped by design. 
The ﬁ ndings varied signiﬁ cantly by study design 
(pheterogeneity<0·0001) with a slightly increased risk of 
ovarian cancer in ever-smokers in prospective studies 
(RR 1·06, 95% CI 1·01–1·11, p=0·02) and in case–control 
studies with population controls (RR 1·08, 95% CI 
1·03–1·14, p=0·003), but an apparent reduced risk in 
studies with hospital controls (RR 0·81, 95% CI 
0·75–0·89, p<0·0001). We could not exclude the 
possibility that hospital controls were more likely to have 
Smoking history (cases/controls)
Ever Never
Relative risk (99% CI)
19 prospective studies
BCDDP (USA)37                         
Nurses' Health Study (USA)46            
RCGP (UK)14                            
IOWA Women's Health (USA)28             
Netherlands Cohort26     
CNBSS (Canada)27                       
CPS–II Mortality (USA)21              
CPS–II Nutrition (USA)38              
NIH–AARP (USA)47                        
EPIC (Europe)50                               
Million Women Study (UK)41            
Other (8 studies)12,25,29,30,36,43,48,49                    
All prospective studies                 
21 case–control studies with population controls
Weiss (USA)6                          
Cramer I (USA)3                        
CASH (USA)16                           
Whittemore (USA)4                      
Risch (Canada)11                       
Green/Purdie (Australia)18             
Mosgaard (Denmark)13                   
Cramer II (USA)15                       
Riman (Sweden)32                      
German OCS22                 
Pike/Wu (USA)31                         
Goodman/Wu (USA)23                      
NISOC Study (Israel)19                 
OVCARE (USA)40                          
SHARE (USA)20                           
Newcomb (Two States; USA)39            
Polish Study42                
AOCS (Australia)44                     
HOPE (USA)51                            
Other (2 studies)7,24                    
All case–control, population controls   
11 case–control studies with hospital controls
Newhouse (UK)2                        
Booth (UK)5                           
Rosenberg (USA)34                       
Negri/Franceschi (Italy)9             
PEDS (USA)35                            
Negri (Italy)17                        
Other (5 studies*)8,10,33,45                    
All case–control, hospital controls     
 
 67/467
 384/1463
 74/330
 57/221
 84/720
 255/959
 1088/4429
 166/589
 377/1611
 324/1247
 1689/6705
 392/1594
 4957/20 335
 
 145/580
 135/124
 310/2285
 123/397
 203/270
 329/322
 573/643
 324/287
 311/1446
 90/207
 239/297
 267/363
 422/724
 199/832
 424/744
 259/1684
 170/1068
 626/601
 331/774
 89/400
 5569/14 048
 
 149/292
 149/286
 488/2198
 238/804
 185/904
 307/752
 91/1108
 1607/6344
 153/717
 279/1244
 102/374
 118/484
 177/1085
 228/973
 1466/6289
 183/810
 386/1441
 445/1852
 1919/7636
 380/1650
 5836/24 555
 
 
 153/557
 113/114
 265/1948
 111/286
 247/294
 464/532
 334/428
 239/238
 491/1915
 191/326
 238/363
 453/532
 920/1538
 179/805
 343/623
 239/1479
 129/926
 800/891
 339/777
 256/515
 6504/15 087
 
 144/305
 139/205
 462/1610
 734/1677
 233/861
 724/1656
 1205/8259
 3641/14 573
0·65 (0·42–1·00)
1·17 (0·92–1·48)
0·88 (0·56–1·39)
1·08 (0·66–1·77)
0·74 (0·50–1·09)
1·13 (0·84–1·53)
1·08 (0·96–1·22)
1·27 (0·92–1·75)
1·01 (0·77–1·32)
1·16 (0·91–1·49)
1·04 (0·94–1·15)
1·08 (0·85–1·38)
1·06 (0·99–1·12)
1·08 (0·71–1·66)
1·07 (0·64–1·79)
1·08 (0·84–1·39)
0·78 (0·50–1·22)
0·97 (0·66–1·41)
1·32 (0·99–1·75)
1·19 (0·92–1·54)
1·04 (0·74–1·47)
0·89 (0·71–1·11)
0·90 (0·56–1·45)
1·15 (0·82–1·62)
0·99 (0·70–1·42)
0·95 (0·78–1·16)
1·04 (0·75–1·43)
1·18 (0·91–1·52)
1·18 (0·90–1·55)
1·21 (0·81–1·80)
1·26 (1·03–1·56)
1·09 (0·82–1·44)
1·09 (0·67–1·79)
1·08 (1·01–1·15)
1·19 (0·78–1·80)
0·71 (0·44–1·13)
0·77 (0·62–0·95)
0·71 (0·56–0·90)
0·76 (0·55–1·06)
1·04 (0·81–1·33)
0·70 (0·49–1·01)
0·81 (0·73–0·91)
0 0·5 1·0 1·5 2·0
Figure 1: Relative risk of ovarian cancer in ever versus never smokers
Stratiﬁ ed by study, age at diagnosis, menopausal status or hysterectomy, body-mass index, and ever use of hormonal therapy and adjusted for parity and duration of 
oral contraceptive use. *Including one unpublished study (Guangzhou, China).
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conditions associated with smoking and thus not be 
representative of smoking habits in the general 
population and so we omitted studies with hospital 
controls from all subsequent analyses.
After excluding studies with hospital controls, we 
found a small increase in the risk of ovarian cancer in 
ever smokers compared with never smokers (RR 1·07, 
95% CI 1·03–1·10, p<0·0001). There was no signiﬁ cant 
heterogeneity in the RR estimates between prospective 
studies and case–control studies with population 
controls, nor between studies within each of these 
designs (p>0·05 for all comparisons). All studies were of 
incident ovarian cancer except one (of fatal ovarian 
cancer21) and results were similar for both incident and 
fatal disease (ﬁ gure 1). 
After further exclusion of the studies unable to 
diﬀ erentiate between current and past smokers, 
the RR of ovarian cancer in ever smokers was 1·06 
(95% CI 1·03–1·09) and was similar in current 
(1·06, 95% CI 1·01–1·11, p=0·01) and in past smokers 
(1·06, 95% CI 1·02–1·11, p=0·003) (ﬁ gure 2). Of the 
22 462 cases of ovarian cancer in ﬁ gure 2, almost 90% 
(19 814) were from studies that had recorded information 
about tumour histology, and the RR estimates for 
current and past smokers were similar when analyses 
were restricted to these women. Most cases in studies 
with recorded histology were epithelial; table 2 shows 
information about tumour subtype and malignant 
potential. There was a 10-year range in mean age at 
diagnosis by subtype, from mean 58·6 (SD 10·4) years 
in women with fully malignant serous tumours to 
48·8 (13·5) years in those with borderline malignant 
serous tumours.
In current versus never smokers, RRs varied 
substantially by histological subtype of the tumour 
(ﬁ gure 2). For mucinous tumours, risk was signiﬁ cantly 
increased in current versus never smokers (RR 1·79, 
95% CI 1·60–2·00, p<0·0001), but for endometrioid and 
for clear-cell tumours, there were signiﬁ cantly reduced 
risks (RR 0·81, 95% CI 0·72–0·92, p=0·001, and RR 
0·80, 95% CI 0·65–0·97, p=0·03, respectively). Serous 
tumours were not signiﬁ cantly associated with current 
smoking (RR 0·99, 95% CI 0·93–1·06, p=0·8). The 
Figure 2: Relative risk of subtypes of ovarian cancer in current and past smokers compared with never smokers
Stratiﬁ ed by study, age at diagnosis, menopausal status or hysterectomy, body-mass index, and ever use of hormonal therapy and adjusted for parity and duration of oral 
contraceptive use. Case–control studies with hospital controls were excluded. The dotted line represents the overall result for all women. NOS=not otherwise speciﬁ ed.
Number of cases in
current/past/never
smokers
Relative risk in past smokers vs 
never smokers (99% CI)
All women                               
All in studies with recorded histology  
All epithelial                          
   Clear-cell                              
   Endometrioid                            
   Mucinous                                
   Serous                                  
   Other or mixed                          
   Epithelial NOS                          
Non-epithelial                          
Malignant tumour NOS                    
 4587/5835/12 040
 4057/5235/10 522
 3803/4914/9819
 159/237/573
 411/574/1375
 735/545/1034
 1751/2494/4841
 552/838/1522
 195/226/474
 79/63/180
 175/258/523
1·06 (1·00–1·13)
1·07 (1·00–1·14)
1·07 (1·00–1·14)
0·80 (0·63–1·01)
0·81 (0·70–0·94)
1·79 (1·47–2·17)
0·99 (0·91–1·08)
1·13 (0·96–1·33)
1·17 (0·88–1·56)
0·90 (0·62–1·30)
1·19 (0·89–1·59)
1·06 (1·00–1·12)
1·05 (0·99–1·11)
1·06 (1·00–1·13)
0·91 (0·73–1·13)
0·92 (0·80–1·06)
1·16 (0·98–1·37)
1·06 (0·98–1·15)
1·14 (0·99–1·31)
1·10 (0·85–1·43)
0·84 (0·57–1·23)
1·01 (0·80–1·27)
0·5 1·0 1·5 2·0 2·5 0·5 1·0 1·5
Relative risk in current smokers vs 
never smokers (99% CI)
Current smokers Past smokers
Number 
of cases
Age at diagnosis 
(years)
Year of 
diagnosis
Cases in studies with recorded histology
All 19 814 57·1 (11·6) 1996 (7)
Non-epithelial 322 49·3 (16·2) 1994 (8)
Epithelial 18 536 57·0 (11·5) 1996 (7)
Malignant NOS 956 61·2 (10·8) 1998 (7)
Epithelial cases*
Clear-cell 969 56·7 (9·5) 1996 (7)
Endometrioid 2360 56·8 (10·3) 1996 (6)
Mucinous 2314 52·4 (13·1) 1995 (7)
Fully malignant 1311 53·7 (12·9) 1995 (7)
Borderline malignant 984 50·3 (13·1) 1996 (7)
Serous 9086 57·3 (11·5) 1996 (7)
Fully malignant 7498 58·6 (10·4) 1996 (7)
Borderline malignant 1389 48·8 (13·5) 1995 (7)
Other 2369 59·5 (10·3) 1997 (6)
Mixed 543 57·8 (11·0) 1999 (6)
Epithelial NOS 895 59·9 (10·9) 1996 (4)
Data are n or mean (SD). Data from case–control studies with hospital controls 
and studies unable to diﬀ erentiate between past and current smoking were 
excluded. NOS=not otherwise speciﬁ ed. *Fully malignant or borderline malignant 
status was not known for all cases; there were only two borderline malignant 
clear-cell, 36 border line malignant endometrioid, and ﬁ ve borderline malignant 
mixed tumours.
Table 2: Distribution and characteristics of subtypes of ovarian cancer in 
studies with recorded histology
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diﬀ erences in smoking-related risk across these four 
speciﬁ c subtypes of epithelial ovarian cancer were 
signiﬁ cant (hetero geneity p<0·0001).
The association between mucinous ovarian cancer and 
current smoking varied further when cancers were 
subdivided by their malignant potential (ﬁ gure 3). The 
increased risk was much greater for borderline malignant 
(RR 2·25, 95% CI 1·91–2·65) than for fully malignant 
mucinous cancers (RR 1·49, 95% CI 1·28–1·73) 
(heterogeneity p=0·01). Neither the increased risk of 
borderline malignant nor that of fully malignant mucinous 
tumours in current smokers were driven by the ﬁ ndings in 
any one study or groups of studies (ﬁ gure 4). For serous 
tumours, the diﬀ erence in risk between borderline 
malignant and fully malignant cancers in current smokers 
was not signiﬁ cant (RR 1·15, 95% CI 0·99–1·33, and RR 
0·96, 95% CI 0·89–1·04; heterogeneity p=0·4; ﬁ gure 3). 
Only 36 borderline malignant endometrioid tumours were 
reported, which was too few to study reliably.
For past smokers compared with never smokers, there 
was a signiﬁ cant increase in the risk of borderline 
malignant mucinous cancers (RR 1·28, 95% CI 
1·06–1·53, p=0·009), but not in the risk of fully 
malignant mucinous tumours (RR 1·08, 95% CI 
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Figure 3: Relative risk of clear-cell, endometrioid, mucinous, and serous epithelial ovarian tumours by malignant potential and smoking history
Stratiﬁ ed by study, age at diagnosis, menopausal status or hysterectomy, body-mass index, and ever use of hormonal therapy and adjusted for parity and duration of 
oral contraceptive use. Case–control studies with hospital controls were excluded. The numbers do not always match those in ﬁ gure 2 because of a few cases with 
missing information about malignant potential.
Prospective studies
Million Women Study (UK)41                       
Other (14 studies)25–30,37,38,43,46–50                             
All prospective studies                           
Case–control studies with population controls
CASH (USA)16                                     
Green/Purdie; AOCS (Australia)18,44      
Mosgaard (Denmark)13                             
Riman (Sweden)32                                 
NISOC Study (Israel)19                           
SHARE (USA)20                                    
Other (13 studies)3,4,6,11,15,22–24,31,39,40,42,51
All case–control, population controls             
Total                                           
 41/109
 63/126
 104/235
 27/13
 13/23
 46/31
 15/29
 13/36
 21/17
 126/244
 261/393
 365/628
1·17 (0·68–2·02)
1·56 (0·88–2·78)
1·37 (0·92–2·03)
3·42 (0·63–18·55)
2·24 (0·49–10·34)
1·47 (0·65–3·31)
1·50 (0·51–4·45)
1·30 (0·44–3·80)
2·63 (0·60–11·58)
1·32 (0·88–1·97)
1·57 (1·16–2·13)
1·49 (1·17–1·89)
 55/79
 19/10
 74/89
 22/11
 25/23
 62/31
 25/34
 20/40
 22/20
 118/149
 294/308
 368/397
1·88 (0·97–3·66)
6·70 (0·39–116·26)
2·31 (1·20–4·46)
3·05 (0·51–18·08)
3·28 (0·71–15·21)
1·88 (0·80–4·43)
1·86 (0·69–5·05)
1·75 (0·62–4·90)
2·68 (0·65–10·98)
2·30 (1·31–4·02)
2·22 (1·55–3·18)
2·25 (1·64–3·08)
0 1·0 2·0 3·0 4·0 5·0 6·0 7·0 0 1·0 2·0 3·0 4·0 5·0 6·0 7·0
Number of cases 
in current/never 
smokers
Relative risk in current smokers vs 
never smokers (99% CI)
Relative risk in current smokers vs 
never smokers (99% CI)
Number of cases
in current/never 
smokers
Fully malignant Borderline malignant
Figure 4: Relative risk of mucinous ovarian cancer in current versus never smokers by study
Stratiﬁ ed by study, age at diagnosis, menopausal status or hysterectomy, body-mass index, and ever use of hormonal therapy and adjusted for parity and duration of oral contraceptive use. 
Case–control studies with hospital controls were excluded. The dotted line represents the overall result for all women.
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0·93–1·26, p=0·3). There was no material increase or 
decrease in risk of other ovarian cancer subtypes in past 
versus never smokers (ﬁ gure 3).
All analyses in ﬁ gures 2–4 were stratiﬁ ed by age, study, 
use of menopausal hormone therapy, menopausal status 
or hysterectomy, and BMI and adjusted by parity and 
duration of oral contraceptive use. Additional adjustment 
by year of birth, ethnic origin, education, family history 
of ovarian or breast cancer, age at menarche, and alcohol 
use changed the RR estimates by less than 2%. 
All Endometrioid Mucinous Serous
Cases in current/
never smokers*
Relative risk 
(99% CI)
Cases in current/
never smokers*
Relative risk 
(99% CI)
Cases in current/
never smokers*
Relative risk 
(99% CI)
Cases in current/
never smokers*
Relative risk 
(99% CI)
All women 4587/12 040 1·06 (1·00–1·13) 411/1375 0·81 (0·70–0·94) 735/1034 1·79 (1·47–2·17) 1751/4841 0·99 (0·91–1·08)
Year of birth
Before 1935 1533/5419 0·99 (0·90–1·09) 130/523 0·87 (0·66–1·14) 160/306 1·92 (1·27–2·91) 482/1949 0·86 (0·74–1·00)
1935 or later 3054/6621 1·11 (1·03–1·20) 281/852 0·79 (0·66–0·95) 575/728 1·75 (1·40–2·18) 1269/2892 1·05 (0·94–1·17)
Age at diagnosis
<60 years 2925/5568 1·09 (1·00–1·18) 296/793 0·78 (0·66–0·93) 569/644 1·77 (1·41–2·23) 1226/2404 1·06 (0·94–1·19)
≥60 years 1662/6472 1·01 (0·92–1·10) 115/582 0·86 (0·66–1·13) 166/390 1·82 (1·26–2·62) 525/2437 0·88 (0·76–1·01)
Ethnic origin
White 3239/7784 1·08 (1·00–1·16) 304/927 0·84 (0·70–1·01) 529/623 1·89 (1·47–2·42) 1238/3087 1·04 (0·93–1·17)
Other 214/691 1·28 (0·89–1·85) 8/80 0·48 (0·20–1·15) 24/75 1·11 (0·42–2·95) 87/258 1·26 (0·71–2·23)
Years of education
<13 years 2902/6664 1·06 (0·98–1·15) 202/569 0·84 (0·67–1·06) 424/510 1·65 (1·27–2·15) 1024/2324 1·00 (0·88–1·13)
≥13 years 1249/4175 1·05 (0·93–1·18) 128/515 0·89 (0·67–1·19) 224/398 1·97 (1·36–2·85) 550/1960 0·96 (0·82–1·12)
Alcohol use
Any 2088/4950 1·10 (1·00–1·20) 184/548 0·85 (0·67–1·08) 310/448 1·79 (1·33–2·41) 788/2104 1·02 (0·89–1·17)
None 919/3758 1·04 (0·91–1·19) 81/508 0·71 (0·52–0·97) 138/322 1·65 (1·08–2·51) 369/1548 0·99 (0·81–1·21)
Body-mass index
<25 kg/m² 2553/5590 1·06 (0·98–1·15) 224/604 0·83 (0·68–1·02) 424/490 1·88 (1·43–2·47) 971/2281 1·00 (0·89–1·13)
≥25 kg/m² 1815/5862 1·04 (0·95–1·14) 171/718 0·78 (0·63–0·97) 272/488 1·64 (1·23–2·19) 683/2310 0·95 (0·83–1·08)
Parity
Parous 3534/9176 1·06 (0·99–1·13) 304/1013 0·78 (0·66–0·92) 582/751 1·87 (1·49–2·35) 1361/3769 0·99 (0·89–1·10)
Nulliparous 922/2374 1·07 (0·90–1·27) 106/326 0·87 (0·58–1·30) 148/261 1·57 (1·00–2·47) 346/888 1·03 (0·80–1·32)
Age at menarche
<13 years 1767/4507 1·09 (0·98–1·21) 163/509 0·84 (0·65–1·08) 246/349 1·81 (1·27–2·57) 656/1797 0·98 (0·84–1·14)
≥13 years 2612/7037 1·08 (1·00–1·17) 230/808 0·85 (0·69–1·04) 450/629 1·81 (1·40–2·35) 1008/2843 1·01 (0·90–1·14)
Oral contraceptives
Ever-use 2075/4163 1·08 (0·98–1·19) 177/512 0·73 (0·59–0·91) 427/463 1·87 (1·41–2·47) 841/1806 1·05 (0·91–1·21)
Never-use 2202/7150 1·03 (0·94–1·12) 207/792 0·86 (0·69–1·08) 253/505 1·72 (1·25–2·36) 777/2686 0·95 (0·83–1·08)
Mother or sister with a history of ovarian or breast cancer
Yes 434/1356 0·98 (0·78–1·23) 51/180 0·79 (0·47–1·33) 56/97 1·51 (0·62–3·66) 196/620 0·99 (0·71–1·39)
No 2178/6114 1·09 (0·99–1·19) 207/811 0·75 (0·61–0·91) 393/575 1·96 (1·48–2·59) 914/2688 1·02 (0·90–1·16)
Menopausal status†
Premenopausal 1333/2623 1·18 (1·04–1·33) 114/364 0·69 (0·54–0·89) 300/380 1·67 (1·25–2·24) 546/1104 1·14 (0·96–1·35)
Postmenopausal 1590/4463 1·02 (0·93–1·12) 137/507 0·75 (0·59–0·95) 249/366 1·82 (1·32–2·50) 593/1693 0·99 (0·86–1·14)
Hysterectomy
Yes 602/1901 1·06 (0·89–1·26) 35/181 0·68 (0·42–1·09) 87/133 1·87 (1·01–3·45) 235/771 0·97 (0·74–1·27)
No 3727/9652 1·06 (0·99–1·13) 345/1123 0·80 (0·69–0·93) 605/848 1·75 (1·43–2·14) 1406/3846 1·01 (0·92–1·11)
Menopausal hormone therapy‡
Ever-use 888/2733 0·95 (0·83–1·08) 98/304 0·91 (0·64–1·29) 103/164 1·73 (1·04–2·88) 348/1236 0·83 (0·69–1·00)
Never-use 1590/4463 1·03 (0·93–1·14) 137/507 0·80 (0·62–1·03) 249/366 1·91 (1·35–2·71) 593/1693 0·97 (0·83–1·13)
In tests for heterogeneity between subgroups no p value implies <0·01. Relative risk (RR) estimates were stratiﬁ ed by study and age at diagnosis, and, where appropriate, menopausal status or hysterectomy, 
body-mass index, and ever use of menopausal hormone therapy, and adjusted by parity and duration of oral contraceptive use. Data from case–control studies with hospital controls were excluded. *Numbers of 
current or never smokers do not always add to the total because of some missing values. †Restricted to never users of menopausal hormone therapy. ‡Analyses relating to use of menopausal hormone therapy 
were restricted to postmenopausal women.
Table 3: Relative risk of all and subtypes of ovarian cancer in current versus never smokers in various subgroups of women
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Furthermore, the observed associations between current 
smoking and overall risk of ovarian cancer, and the risk 
in the endometrioid, mucinous, and serous subtypes, did 
not vary substantially by year of birth, age at diagnosis, 
ethnic origin, education, alcohol use, BMI, parity, age at 
menarche, use of oral contraceptives, having a ﬁ rst-
degree relative with ovarian or breast cancer, menopausal 
status, hysterectomy, or use of menopausal hormone 
therapy (table 3). There were too few clear-cell tumours to 
compare reliably the association with smoking between 
subgroups.
There was no signiﬁ cant heterogeneity between 
prospective studies and case–control studies with 
population controls in the association between current 
smoking and ovarian cancer risk overall (heterogeneity 
p=0·2) or when analyses were restricted to mucinous, 
endometrioid, and serous tumour subtypes (hetero geneity: 
mucinous, p=0·2; endometrioid, p=0·4; serous, p=0·07).
Discussion
This collaboration has brought together and reanalysed 
individual participant data for about 28 000 women with 
ovarian cancer from 51 studies of the eﬀ ect of smoking 
on ovarian cancer incidence. These studies provide 
almost all the available epidemiological evidence 
worldwide on the topic. Although current smoking was 
associated with an excess of mucinous ovarian cancer, as 
had been reported previously,1 we found that the increase 
was mainly in tumours of borderline malignancy rather 
than in fully malignant tumours. Furthermore, current 
smoking was associated with deﬁ cits in two other 
subtypes of ovarian cancer—endometrioid and clear-cell 
tumours. Hence, smoking had little net eﬀ ect on the 
overall ovarian cancer incidence. The signiﬁ cant adverse 
and favourable eﬀ ects of current smoking were 
attenuated in past smokers, so past smoking had little 
net eﬀ ect on ovarian cancer incidence.
Results of case–control studies that used hospital 
controls diﬀ ered qualitatively from those of studies that 
used other designs. These diﬀ erences are unlikely to be 
due merely to selectively inaccurate retrospective 
reporting of smoking, since the results diﬀ er sub-
stantially between the retrospective studies using hospital 
controls and the retrospective studies using population 
controls. Since smoking is associated with various 
diseases that could lead to hospital admission it is 
plausible that, on average, the hospital controls were 
more likely to smoke than were women in the general 
population. This diﬀ erence would dilute, and could even 
reverse, an association between smoking and ovarian 
cancer risk, as suggested by ﬁ gure 1. For this reason, we 
omitted studies with hospital controls from the main 
analyses. Nevertheless, to ensure that all the epi-
demiological information is published, details of those 
studies are included in table 1 and in ﬁ gure 1.
Even in case–control studies with population controls 
there might have been some diﬀ erential participation by 
smoking history and the retrospective reporting of 
smoking might have been diﬀ erentially aﬀ ected by the 
cases’ knowledge that they had ovarian cancer. Although 
these possibilities cannot be excluded, the similarity of 
the ﬁ ndings in case–control studies with population 
controls and in studies with prospective recording of 
smoking suggests that they might not be a serious issue 
here.
An advantage of seeking to review all epidemiological 
studies of ovarian cancer with information on smoking, 
published and unpublished, is that this helps to avoid 
unduly selective emphasis on published results or on just 
some studies. Only a third of eligible studies have 
published on the association between smoking and risk of 
ovarian cancer, so reviews based solely on published 
studies could have been susceptible to publication bias. 
Eligible studies that did not contribute data to this 
collaboration, but had published on ovarian cancer risk 
associated with smoking,53,54,56 together contain fewer than 
a tenth as many cases as are included in the present 
analyses. Failure to include these studies would not have 
substantially changed the associations reported here, 
because their published ﬁ ndings are broadly similar to our 
ﬁ ndings. Despite extensive eﬀ orts to identify all studies 
with unpublished results, a guarantee that others do not 
exist is clearly impossible. Furthermore, to have completely 
up-to-date information from continuing prospective 
studies that are accumulating data beyond the time when 
information was contributed to this collaboration is not 
possible. Ongoing prospective studies will continue to 
accrue women with ovarian cancer, but there is no good 
reason to expect that these additional data will materially 
change the evidence that is already available.
A further advantage of bringing together worldwide 
evidence on the association between ovarian cancer and 
smoking is that large numbers of cases are needed to 
assess reliably whether the association varies by tumour 
subtype. The histological classiﬁ cations used were 
those provided by investigators for each study. The 
classiﬁ cation of ovarian cancers by histology and by 
malignant potential might have varied between studies 
and possibly also over time. Misclassiﬁ cation of tumour 
subtype would tend to dilute RR estimates, and blur 
diﬀ erences between them, yet sharp diﬀ erences in the 
smoking-related risks were found (similar diﬀ erences by 
tumour subtype were not found for other factors such as 
oral contraceptive use and adiposity57,59).
The ﬁ ndings for diﬀ erent tumour subtypes were not 
driven by the results from any one study or group of 
studies and are unlikely to be due to confounding. All 
analyses were routinely stratiﬁ ed by age, study, use of 
menopausal hormone therapy, menopausal status, and 
BMI and were adjusted by parity and oral contraceptive 
use; additional adjustment for six other factors hardly 
changed the RR estimates.
The large proportional increase in risk of mucinous 
ovarian tumours associated with current smoking, and 
Articles
954 www.thelancet.com/oncology   Vol 13   September 2012
the diﬀ erences between the proportional increases in 
fully malignant and in borderline malignant mucinous 
tumours, are both deﬁ nite ﬁ ndings and could reﬂ ect a 
real eﬀ ect of smoking. Moreover, the excess risk of 
mucinous tumours was far greater in current than in 
past smokers. Although borderline malignant mucinous 
tumours are less aggressive than fully malignant 
mucinous tumours, they can have microinvasive or 
invasive components.60 The proportional reductions in 
smoking-related risks of clear-cell and endometrioid 
tumours, although not as great as the proportional 
increase in mucinous tumours, could also be a real eﬀ ect 
of smoking. Since information about the amount smoked 
and the timing of exposure was not sought systematically 
for this collaboration, little could be done to examine 
these associations further.
Smoking is known to aﬀ ect the ovaries, in that smokers 
have an earlier menopause than do non-smokers,61 but 
this eﬀ ect does not necessarily imply that smoking would 
aﬀ ect ovarian cancer incidence or have diﬀ erent eﬀ ects 
on diﬀ erent tumour subtypes. The ﬁ ndings here support 
the view that diﬀ erent subtypes of ovarian cancer might 
originate in diﬀ erent types of cells. In particular, 
endometrial cancer risk is reduced in smokers62 and our 
ﬁ nding of a reduced risk of endometrioid tumours in 
current smokers is consistent with the hypothesis that 
endometrioid ovarian cancers might have their origin in 
endometrial cells. No equivalent analogy exists for clear-
cell tumours.
Smoking has a wide range of adverse eﬀ ects resulting 
in large increases in mortality from many speciﬁ c 
causes.63 Although the excess of mucinous tumours in 
smokers is deﬁ nite, it seems to be counterbalanced by a 
small deﬁ cit in clear-cell and endometrioid tumours. 
Hence, the overall increase in incidence of ovarian cancer 
in smokers is small and, even in this extensive dataset, 
barely signiﬁ cant. This study could not address survival, 
but since about half the mucinous tumours in smokers 
were of borderline malignancy, smoking is likely to have 
little net eﬀ ect on mortality from ovarian cancer.
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